Regen Lab SA
Regen Lab SA, founded in 2003, is a global leader in regenerative medicine, specializing in the design and manufacturing of high-quality medical devices for cell therapies, including autologous platelet-rich plasma (PRP) and advanced cell therapy treatments. The company is committed to innovation, quality, and effective therapeutic solutions, with a strong presence in over 90 countries and a history of pioneering products and technologies in the field of regenerative medicine.
Industries
Nr. of Employees
small (1-50)
Regen Lab SA
Products
Closed-system PRP preparation kit (blood collection tubes with separator gel)
Single-use vacuum blood collection tubes containing a separator gel and anticoagulant designed for sterile mechanical separation of plasma and platelets to produce standardized platelet-rich plasma.
Closed-system PRP plus hyaluronic acid combination kit for intra-articular application
Closed-system product enabling combination of autologous platelet-rich plasma with non-cross-linked hyaluronic acid for intra-articular injection workflows.
Components for autologous thrombin-enriched PRP preparation
Consumables and accessories to generate autologous thrombin-enriched platelet preparations intended to enhance fibrin formation and clot characteristics for tissue-regeneration procedures.
Extracellular matrix scaffold materials enriched with autologous PRP
Biologic scaffold materials intended to be combined with platelet-rich plasma to provide a matrix for cell migration and tissue regeneration.
Closed-system PRP preparation kit (blood collection tubes with separator gel)
Single-use vacuum blood collection tubes containing a separator gel and anticoagulant designed for sterile mechanical separation of plasma and platelets to produce standardized platelet-rich plasma.
Closed-system PRP plus hyaluronic acid combination kit for intra-articular application
Closed-system product enabling combination of autologous platelet-rich plasma with non-cross-linked hyaluronic acid for intra-articular injection workflows.
Components for autologous thrombin-enriched PRP preparation
Consumables and accessories to generate autologous thrombin-enriched platelet preparations intended to enhance fibrin formation and clot characteristics for tissue-regeneration procedures.
Extracellular matrix scaffold materials enriched with autologous PRP
Biologic scaffold materials intended to be combined with platelet-rich plasma to provide a matrix for cell migration and tissue regeneration.
Services
Webinars, symposiums and congress activities to train and inform healthcare professionals on autologous PRP workflows and combination regenerative therapies.
Documentation and compliance guidance for ISO 13485, CE marking pathways and EU Authorized Representative requirements relevant to medical device market access.
Webinars, symposiums and congress activities to train and inform healthcare professionals on autologous PRP workflows and combination regenerative therapies.
Documentation and compliance guidance for ISO 13485, CE marking pathways and EU Authorized Representative requirements relevant to medical device market access.
Expertise Areas
- Autologous regenerative medicine (PRP-based therapies)
- Medical device development for cell-therapy workflows
- GMP medical device manufacturing
- Formulation development for combination regenerative therapies
Key Technologies
- Separator gel-based blood component separation
- Closed-system blood collection tubes with vacuum
- Centrifugation-based platelet-rich plasma (PRP) preparation
- Leukocyte-reduced PRP production
News & Updates
RegenLab USA has opened a new R&D and manufacturing facility in Jersey City, enhancing its capabilities in regenerative medicine.
Regen Lab will participate in IMCAS Asia 2025, showcasing its latest regenerative solutions.
A clinical study on the effectiveness of RegenPRP™ combined with ATS in treating chronic wounds.
A study on the use of RegenPRP™ combined with ATS for chronic wound treatment.
A clinical study highlighting the use of RegenPRP™-HA for facial rejuvenation.
A study on the use of RegenPRP™ for Achilles tendinopathies.
RegenLab USA has opened a new R&D and manufacturing facility in Jersey City, enhancing its capabilities in regenerative medicine.
Regen Lab will participate in IMCAS Asia 2025, showcasing its latest regenerative solutions.
A clinical study on the effectiveness of RegenPRP™ combined with ATS in treating chronic wounds.
A study on the use of RegenPRP™ combined with ATS for chronic wound treatment.
A clinical study highlighting the use of RegenPRP™-HA for facial rejuvenation.
A study on the use of RegenPRP™ for Achilles tendinopathies.